Mylan announced that BLA and marketing authorisation under review by FDA and European authorities, biosimilar insulin and aflibercept projects remain on target

JD Supra reports on Mylan’s Q1 earnings call. In the call, Mylan announced that the BLA and marketing authorisation for its bevacizumab candidate is currently under review by the FDA and European authorities. Mylan also confirmed that its biosimilar insulin and aflibercept projects remain on target.